tbuckley/cabot-search huggingface dataset:
565P Selinexor in combination with topotecan in patients with advanced or metastatic solid tumours: Results of an open label, single-center, multi-arm phase Ib study
Authors: K.Z. Thein, A.M. Tsimberidou, S. Piha-Paul, F. Janku, D.D. Karp, S. Fu, A. Zarifa, J. Gong, D.S. Hong, T.A. Yap, V. Subbiah, S. Pant, F. Meric-Bernstam, A. Naing
Journal: Annals of Oncology (2020)
628P Treatment in CARD eligible metastatic castration resistant prostate cancer (mCRPC) patients according to the status of germline HRR mutations: Cabazitaxel (CBZ) vs enzalutamide/abiraterone
Authors: C. Llacer Perez, N. Romero Laorden, R. Lozano Mejorada, J.M. Piulats, J. Puente, D. Lorente Estelles, A. Medina, C. Cattrini, F.M. Vitrone, E. Almagro, P. Borrega García, N. Lainez, L. Rivera, R. Villatoro, A. Hernández, A. Rodriguez-Vida, P.P. López-Casas, E. Gallardo, E. Castro Marcos, D. Olmos Hidalgo
Journal: Annals of Oncology (2020)
845P Clinical utility of monitoring TP53 mutation (TP53m) circulating tumour DNA (ctDNA) in patients (pts) with high-grade ovarian carcinomas (HGOC)
Authors: M. Kfoury, C. Bonnet, N. Delanoy, A. Leformal, C. Brizais, K. Howarth, C. Morris, P. Pautier, E. Colomba-Blameble, S. Gouy, P. Morice, A. Maulard, L. Elodie, A. Leary
Journal: Annals of Oncology (2020)
Endoscopic sigmoidorectal reanastomosis using a dual endoscope technique: rendezvous single-balloon enteroscopy and endoscopic ultrasound
Authors: Sławomir Kozieł, Katarzyna Kozłowska-Petriczko, Katarzyna M. Pawlak, Jan Petriczko, Anna Wiechowska-Kozłowska
Journal: Endoscopy (2020)

While therapeutic endoscopic ultrasound (EUS) has shown promising results as a new modality to create EUS-guided gastroenterostomy using a lumen-apposing metal stent (LAMS), little data exist on its use as a rendezvous technique. We present a case of endoscopic reanastomosis using rendezvous single-balloon enteroscopy and EUS in a patient with complete sigmoid obstruction.
504P Primary tumour location impacts oncological outcome of patients with resected colorectal liver metastases
Authors: V.E. Pacheco-Barcia, B. Vera Cea, A. Garrido, O. Donnay, P. Toquero Diez, R. Mondejar, R. Serrano, E. Martin, N. Romero Laorden, M. di Martino, L. Del Campo, R. Colomer Bosch
Journal: Annals of Oncology (2020)
620P Pembrolizumab (pembro) plus docetaxel and prednisone in patients with abiraterone acetate (abi)- or enzalutamide (enza)–pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B update
Authors: E. Romano, S.S. Sridhar, M.P. Kolinsky, G. Gravis, L. Mourey, J.M. Piulats, W.R. Berry, H. Gurney, M. Retz, L.J. Appleman, M. Boegemann, J.S. de Bono, A.M. Joshua, U. Emmenegger, H.J. Conter, B. Laguerre, H. Wu, P. Qiu, C. Schloss, E.Y. Yu
Journal: Annals of Oncology (2020)
408P A prospective controlled trial of the efficacy of uracil and tegafur/leucovorin for stage II colon cancer with risk factors for recurrence using propensity score-based methods (JFMC46-1201)
Authors: T. Takahashi, S. Sadahiro, K. Sakamoto, T. Tsuchiya, H. Ohge, T. Sato, K. Kondo, Y. Ogata, H. Baba, M. Itabashi, M. Ikeda, M. Hamada, M. Kusano, I. Hyodo, J. Sakamoto, M. Taguri, S. Morita
Journal: Annals of Oncology (2020)
LBA84 Consolidation ipilimumab and nivolumab vs observation in limited stage SCLC after chemo-radiotherapy: Results from the ETOP/IFCT 4-12 STIMULI trial
Authors: S. Peters, J-L. Pujol, U. Dafni, M. Dómine, A. Becker, J. Andrade, A. Curioni-Fontecedro, O. Molinier, D. Moro-Sibilot, K. Nackaerts, A. Insa Mollá, G. López Vivanco, J. Madelaine, S. Popat, M. Reck, H. Roschitzki-Voser, P. Mitchell, D. De Ruysscher, C. Le Pechoux, R. Stahel
Journal: Annals of Oncology (2020)
Promoterless, Nuclease‐Free Genome Editing Confers a Growth Advantage for Corrected Hepatocytes in Mice With Methylmalonic Acidemia
Authors: Randy J. Chandler, Leah E. Venturoni, Jing Liao, Brandon T. Hubbard, Jessica L. Schneller, Victoria Hoffmann, Susana Gordo, Shengwen Zang, Chih‐Wei Ko, Nelson Chau, Kyle Chiang, Mark A. Kay, Adi Barzel, Charles P. Venditti
Journal: Hepatology (2020)

Adeno-associated viral (AAV) gene therapy has shown great promise as an alternative treatment for metabolic disorders managed using liver transplantation, but remains limited by transgene loss and genotoxicity. Our study aims to test an AAV vector with a promoterless integrating cassette, designed to provide sustained hepatic transgene expression and reduced toxicity in comparison to canonical AAV therapy.
1092P Non-progression with avelumab treatment in patients with metastatic Merkel cell carcinoma (mMCC) is associated with a clinically meaningful better health-related quality of life compared with progressive disease
Authors: M. Bharmal, S. Nolte, C. Lebbé, L. Mortier, A.S. Brohl, N. Fazio, J-J. Grob, N. Prinzi, G.J. Hanna, J. Hassel, F. Kiecker, B. Ellers-Lenz, M. Bajars, G. Guezel, P. Nghiem, M. Hunger, M. Schlichting, M. Henry-Szatkowski, S. D'Angelo
Journal: Annals of Oncology (2020)
910O Primary results of the phase III JAVELIN head &amp; neck 100 trial: Avelumab plus chemoradiotherapy (CRT) followed by avelumab maintenance vs CRT in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN)
Authors: E.E. Cohen, R.L. Ferris, A. Psyrri, R. Haddad, M. Tahara, J. Bourhis, K.J. Harrington, P.M-H. Chang, J-C. Lin, M. Razaq, M.M. Teixeira, J. Lovey, J. Chamois, A. Rueda Dominguez, C. Hu, M. Dvorkin, S. De Beukelaer, D. Pavlov, H. Thurm, N. Lee
Journal: Annals of Oncology (2020)

Despite high-dose, cisplatin-containing, multimodality therapy, LA SCCHN ultimately recurs in many patients. This trial investigated whether avelumab, a human anti–PD-L1 antibody, improved progression-free survival (PFS) when combined with concurrent CRT followed by avelumab maintenance. This randomized, double-blind, placebo-controlled phase III trial (JAVELIN Head and Neck 100; NCT02952586) included patients with histologically confirmed, previously untreated LA SCCHN of the oropharynx, hypopharynx, larynx, or oral cavity eligible for definitive CRT with curative intent. Patients were required to have stage III, IVa, or IVb disease per AJCC (7th edition) except for HPV+ oropharyngeal patients, for whom only T4 or N2c or N3 status was allowed. Patients were randomized 1:1 to receive avelumab 10 mg/kg IV Q2W + CRT (cisplatin 100 mg/m2 Q3W + standard fractionation of 70 Gy in 35 fractions over 7 weeks) or placebo + CRT. This was preceded by a lead-in dose and followed by avelumab or placebo maintenance therapy for up to 1 year. The primary endpoint was PFS by investigator assessment per modified RECIST v1.1; interim analysis was planned at ≈ 217 events. 697 patients were randomized (avelumab arm, n=350; placebo arm, n=347); baseline characteristics were similar in both arms. At interim analysis, the hazard ratios for PFS per modified RECIST v1.1 (based on 224 events) and overall survival (OS; based on 131 deaths) were 1.21 (95% CI: 0.93-1.57; p=0.920) and 1.31 (95% CI: 0.93-1.85; p=0.937), respectively, both in favor of placebo + CRT. Median PFS and OS were not reached in either arm. Grade ≥3 adverse events (AEs) were more frequent with avelumab + CRT vs placebo + CRT (88% vs 82%); fatal AEs occurred in 6% and 5%, respectively. Rates of AEs leading to discontinuation of any study drug were similar in both arms (33% vs 32% in the avelumab vs placebo arms). Tolerability was similar in both arms; however, the study did not demonstrate statistically significant improvement in PFS with avelumab + CRT vs placebo + CRT. These results may inform future trial design.
754P Ibrutinib (Ibr) in combination with paclitaxel (Pac) has activity in patients (Pts) with advanced urothelial carcinoma (aUC): Final analysis of a phase Ib/II study
Authors: D. Castellano Gauna, R. Morales-Barrera, I. Duran, D-Y. Oh, I.J. Chung, T. Arkenau, U.N. Vaishampayan, M. Tuthill, P. Gajate Borau, S.J. Shin, S.P. Dang, C-H. Ju, E. Chong, I. Lal, G. Cole, O. Reig Torras
Journal: Annals of Oncology (2020)
1882P Sexual functioning in women with solid malignancies: Often neglected but an essential hardship
Authors: S. Shwetha, L.A. Jacob, D. Lokanatha, M.C. Sureshbabu, K.N. Lokesh, L.K. Rajeev, A.H. Rudresh, S.C. Saldanha
Journal: Annals of Oncology (2020)
1771P Do breast cancer patients with COVID-19 have a poor prognosis? Experience in a hospital in Madrid
Authors: B. Obispo, J. Rogado, G. Serrano-Montero, A. Lopez-Alfonso, A. Martin Marino, C. Pangua Mendez, M. Perez-Perez, M.A. Lara
Journal: Annals of Oncology (2020)
921P Pembrolizumab plus docetaxel for the treatment of recurrent metastatic head and neck cancer: A prospective phase I/II study
Authors: T. Fuereder, C. Minichsdorfer, M. Mittlboeck, C. Wagner, F. Oberndorfer, L. Müllauer, M-B. Aretin, C. Czerny, U. Schwarz-Nemec
Journal: Annals of Oncology (2020)
Preliminary predictive criteria for COVID-19 cytokine storm
Authors: Roberto Caricchio, Marcello Gallucci, Chandra Dass, Xinyan Zhang, Stefania Gallucci, David Fleece, Michael Bromberg, Gerard J Criner
Journal: Annals of the Rheumatic Diseases (2020)

To develop predictive criteria for COVID-19-associated cytokine storm (CS), a severe hyperimmune response that results in organ damage in some patients infected with COVID-19. We hypothesised that criteria for inflammation and cell death would predict this type of CS.We analysed 513 hospitalised patients who were positive for COVID-19 reverse transcriptase PCR and for ground-glass opacity by chest high-resolution CT. To achieve an early diagnosis, we analysed the laboratory results of the first 7 days of hospitalisation. We implemented logistic regression and principal component analysis to determine the predictive criteria. We used a 'genetic algorithm' to derive the cut-offs for each laboratory result. We validated the criteria with a second cohort of 258 patients.We found that the criteria for macrophage activation syndrome, haemophagocytic lymphohistiocytosis and the HScore did not identify the COVID-19 cytokine storm (COVID-CS). We developed new predictive criteria, with sensitivity and specificity of 0.85 and 0.80, respectively, comprising three clusters of laboratory results that involve (1) inflammation, (2) cell death and tissue damage, and (3) prerenal electrolyte imbalance. The criteria identified patients with longer hospitalisation and increased mortality. These results highlight the relevance of hyperinflammation and tissue damage in the COVID-CS.We propose new early predictive criteria to identify the CS occurring in patients with COVID-19. The criteria can be readily used in clinical practice to determine the need for an early therapeutic regimen, block the hyperimmune response and possibly decrease mortality.
Nationwide outbreak of invasive listeriosis associated with consumption of meat products in health care facilities, Germany, 2014–2019
Authors: Raskit Lachmann, Sven Halbedel, Marlen Adler, Natalie Becker, Franz Allerberger, Alexandra Holzer, Idesbald Boone, Gerhard Falkenhorst, Sylvia Kleta, Sascha Al Dahouk, Klaus Stark, Petra Luber, Antje Flieger, Hendrik Wilking
Journal: Clinical Microbiology and Infection (2020)
Disruptive Synergy: Melding of Human Genetics and Clinical Assisted Reproduction
Authors: Eli Y. Adashi, I. Glenn Cohen
Journal: Cell Reports Medicine (2020)

The melding of human genetics with clinical assisted reproduction, now all but self-evident, gave flight to diagnostic and therapeutic approaches previously deemed infeasible. Preimplantation genetic diagnosis, mitochondrial replacement techniques, and remedial germline editing are particularly noteworthy. Here we explore the relevant disruption brought forth by coalescence of these mutually enabling disciplines with the regulatory and legal implications thereof.
561P Phase Ib study of ribociclib (R) + trametinib (T) in patients (pts) with metastatic/advanced solid tumours
Authors: P. LoRusso, M. Fakih, F.Y.F.L. De Vos, J.T. Beck, J. Merchan, G. Shapiro, C-C. Lin, J. Desai, J. Spratlin, T. Cascella, L. Sandalic, A.M. Abdelhady, A. Boran, E. Gasal, F. Janku, E. Van Cutsem
Journal: Annals of Oncology (2020)

In preclinical and preliminary clinical studies, the combined inhibition of MEK and CDK4/6 showed synergistic antitumor activity. This study aimed to determine the recommended phase II regimen (RP2R) and characterize the safety and preliminary efficacy of T (MEK inhibitor) in combination with R (CDK4/6 inhibitor) in pts with advanced solid tumours. Adult pts with advanced/metastatic solid tumours who failed ≥ 1 prior line of systemic therapy were enrolled in this multicenter, open-label study (NCT02703571). Here, we report results from the phase Ib part of the study. The safety of T (dose range, 1-2 mg) + R (dose range, 200-500 mg) was assessed across 11 cohorts using 2 different treatment schedules. The initial 28-day cycle of continuous T (2 mg) + 3W on/1W off R (200 mg) was modified to an intermittent schedule for safety reasons. A 21-day schedule of 2W on/1W off T + R was then explored. The primary objective was to determine maximum tolerated dose (MTD) and/or RP2R of the combination. The secondary objectives included safety, preliminary antitumor activity, and pharmacokinetics (PK). Biomarker analyses are ongoing as part of the exploratory objectives. A total of 95 pts were enrolled between June 2016 and September 2019. The median age was 58 y; 31% of the pts were aged ≥ 65 years. The primary sites of cancer at initial diagnosis were colon (27%), rectum (13%), and pancreas (11%). The median time since most recent relapse/progression to study entry was 2 mo. In the dose-determining set (n = 79), 12 pts (15%) experienced a dose-limiting toxicity. All pts (n = 95) experienced at least 1 adverse event (AE); most common was fatigue (57%). Serious AEs were reported in 42% of the pts. RP2R was T 1 mg + R 300 mg and MTD was T 1 mg + R 400 mg (T on W 1 and 2 + R on W 2 and 3 of a 21-day schedule). The objective response rate using RECIST 1.1 was 4%. The median progression-free survival was 2.6 mo. An increasing trend in T exposure was observed with increasing R dose. RP2R and MTD for T + R oral coadministration were established. The safety and tolerability profile of T + R combination was consistent with the prior experience as single agents. The efficacy of this combination was limited; phase 2 portion of the study was not pursued.
1698P The presence of COVID-19 makes more cancer patients distressed and time perception may distinguish them
Authors: N.V. Conev, M. Petrova, E. Dimitrova, K. Zhelev, Z.I. Zahariev, K. Nikolov, T. Popov, M. Ivanova, N. Evgeniev, I. Shterev Donev
Journal: Annals of Oncology (2020)
540P Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy
Authors: S.V. Liu, F. De Braud, A. Drilon, R.C. Doebele, M.R. Patel, B.C. Cho, M-J. Ahn, C-H. Chiu, A.F. Farago, K. Goto, J. Lee, Y. Ohe, S-H.I. Ou, P. Cassier, D.S.W. Tan, G.A. Otterson, L. Veronese, S. Osborne, B. Simmons, S. Siena
Journal: Annals of Oncology (2020)
1026MO Phase Ib dose escalation study of novel immunogenic cell death (ICD) inducer PT-112 plus PD-L1 inhibitor avelumab in solid tumours
Authors: D.D. Karp, R.S. Dronca, R. Camidge, B.A. Costello, A.S. Mansfield, T.D. Ames, J.M. Jimeno, A.H. Bryce
Journal: Annals of Oncology (2020)
The global burden of neck pain: estimates from the Global Burden of Disease 2010 study
Authors: Damian Hoy, Lyn March, Anthony Woolf, Fiona Blyth, Peter Brooks, Emma Smith, Theo Vos, Jan Barendregt, Jed Blore, Chris Murray, Roy Burstein, Rachelle Buchbinder
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Objective</h3> To estimate the global burden of neck pain. <h3>Methods</h3> Neck pain was defined as pain in the neck with or without pain referred into one or both upper limbs that lasts for at least 1 day. Systematic reviews were performed of the prevalence, incidence, remission, duration and mortality risk of neck pain. Four levels of severity were identified for neck pain with and without arm pain, each with their own disability weights. A Bayesian meta-regression method was used to pool prevalence and derive missing age/sex/region/year values. The disability weights were applied to prevalence values to derive the overall disability of neck pain expressed as years lived with disability (YLDs). YLDs have the same value as disability-adjusted life years as there is no evidence of mortality associated with neck pain. <h3>Results</h3> The global point prevalence of neck pain was 4.9% (95% CI 4.6 to 5.3). Disability-adjusted life years increased from 23.9 million (95% CI 16.5 to 33.1) in 1990 to 33.6 million (95% CI 23.5 to 46.5) in 2010. Out of all 291 conditions studied in the Global Burden of Disease 2010 Study, neck pain ranked 4th highest in terms of disability as measured by YLDs, and 21st in terms of overall burden. <h3>Conclusions</h3> Neck pain is a common condition that causes substantial disability. With aging global populations, further research is urgently needed to better understand the predictors and clinical course of neck pain, as well as the ways in which neck pain can be prevented and better managed.
68Ga-DOTATATE and 18F-FDG in Castleman Disease
Authors: Alinne Fernanda Amaral Verçosa, Maria Eduarda Duarte de Mello Flamini, Luiz Victor Maia Loureiro, Rodrigo de Carvalho Flamini
Journal: Clinical Nuclear Medicine (2020)

Abstract A 35-year-old woman with rectal neuroendocrine tumor, Ki-67 proliferation index less than 2%, and a mediastinal mass on CT postoperatively was referred for restaging with PET/CT 68 Ga-DOTATATE. The examination showed uptake on the pelvic lymph node and mediastinal mass. Because of differences in lesions’ SUVs and clinical presentation, the hypothesis of lymphoma for the mediastinal mass was raised, and 18 F-FDG PET/CT was performed, which showed glycolytic hypermetabolism in the mediastinal mass and absence of hypermetabolism in pelvic lymph nodes. Transthoracic biopsy of the mass revealed atypical large-cell lymphoid proliferation, and immunohistochemistry study was compatible with Castleman disease.
CN6 Health literacy in informal carers in relation to breast cancer prevention: A qualitative research in three European countries
Authors: T.A. Theologia, A. Charalambous, M.C. Fella, A. Christou, J.B. Alves, A.R. Teixeira, L.B. Boccaletti, S. Beccati, M. Tagliani, A. Palermo
Journal: Annals of Oncology (2020)
640P Quality of life and survival in elderly metastatic castration-resistant prostate cancer (mCRPC) patients (Pts) treated with docetaxel
Authors: I. Paredero Perez, M. Arnal, D. Lorente, R. Girones Sarrio, R. Lozano Mejorada, N. Romero Laorden, C. Llacer Perez, E. Castro Marcos, D. Olmos, A. Sanchez Hernandez
Journal: Annals of Oncology (2020)
721P Ipilimumab and nivolumab compassionate use program in metastatic renal cell carcinoma patients with intermediate or poor IMDC risk score: The large multicenter Italian study
Authors: U. Basso, F. Paolieri, C.G. Porta, U. De Giorgi, S. Bracarda, L. Antonuzzo, F. Atzori, G. Cartenì, G. Procopio, L. Fratino, M. D'Arcangelo, G. Fornarini, P.A. Zucali, A. Cusmai, M. Santoni, C. Baldessari, E. Naglieri, S. Panni, V. Zagonel, G. Tortora
Journal: Annals of Oncology (2020)
Dapagliflozin in Patients with Chronic Kidney Disease
Authors: Hiddo J.L. Heerspink, Bergur V. Stefánsson, Ricardo Correa-Rotter, Glenn M. Chertow, Tom Greene, Fan-Fan Hou, Johannes F.E. Mann, John J.V. McMurray, Magnus Lindberg, Peter Rossing, C. David Sjöström, Roberto D. Toto, Anna-Maria Langkilde, David C. Wheeler
Journal: New England Journal of Medicine (2020)

Patients with chronic kidney disease have a high risk of adverse kidney and cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease, with or without type 2 diabetes, is not known.
923P Immune alterations in a window of opportunity for durvalumab (MEDI4736) plus metformin trial in squamous cell carcinoma of the head and neck (SCCHN)
Authors: J.M. Curry, U. Nwagu, L. Harshyne, A. Linnenbach, N. Srivastava, D.M. Cognetti, A. Luginbuhl, R. Zinner, R. Axelrod, V. Bar-Ad, R.A. Goldman, U. Rodeck, U. Martinez-Outschoorn, J.M. Johnson, A. Argiris
Journal: Annals of Oncology (2020)
1549P Molecular alterations (MA) with potential therapeutic implications in KRAS wild-type (WT) pancreatic cancer patients
Authors: D.A. Acosta Eyzaguirre, H. Verdaguer, E. Buxò, A. Garcia-Alvarez, E. Sardo, J. Hernando, M. Diez Garcia, M. Guardiola, F.J. Ros Montañá, I. Baraibar Argota, N. Saoudi, D.H. Marmolejo Castaneda, S. Aguilar, A. Sierra, A. Vivancos, R. Dienstmann, T. Macarulla Mercadé
Journal: Annals of Oncology (2020)
446P Real-world data (RWD) survival analysis of first line (1L) metastatic colorectal cancer (mCRC) patients (pts) with BRAF V600 and non-V600, KRAS G12 and G13, and NRAS mutations
Authors: A. Gershon, R. Machado, H. Trinh, C. Julian, Z. Shi, Q. Zhang, Y. Yan
Journal: Annals of Oncology (2020)
166MO A phase III trial to compare the efficacy, safety, pharmacokinetics and immunogenicity of HD201 to trastuzumab in HER2+ early breast cancer patients (TROIKA)
Authors: P. Xavier, C.S.J. Hii, K. Mclendon, P. Feyaerts, A. Felicia, None J. litha, M.F. Demarchi, P. Coliat, F. Deforce, M.P. Derde, M.J. Kim, L.S. Park
Journal: Annals of Oncology (2020)
Ionic Mechanisms of Impulse Propagation Failure in the FHF2-Deficient Heart
Authors: David S. Park, Akshay Shekhar, John Santucci, Gabriel Redel-Traub, Sergio Solinas, Shana Mintz, Xianming Lin, Ernest Whanwook Chang, Deven Narke, Yuhe Xia, Mitchell Goldfarb, Glenn I. Fishman
Journal: Circulation Research (2020)

FHFs (fibroblast growth factor homologous factors) are key regulators of sodium channel (NaV) inactivation. Mutations in these critical proteins have been implicated in human diseases including Brugada syndrome, idiopathic ventricular arrhythmias, and epileptic encephalopathy. The underlying ionic mechanisms by which reduced Nav availability in Fhf2 knockout (Fhf2KO) mice predisposes to abnormal excitability at the tissue level are not well defined.Using animal models and theoretical multicellular linear strands, we examined how FHF2 orchestrates the interdependency of sodium, calcium, and gap junctional conductances to safeguard cardiac conduction.Fhf2KO mice were challenged by reducing calcium conductance (gCaV) using verapamil or by reducing gap junctional conductance (Gj) using carbenoxolone or by backcrossing into a cardiomyocyte-specific Cx43 (connexin 43) heterozygous background. All conditions produced conduction block in Fhf2KO mice, with Fhf2 wild-type (Fhf2WT) mice showing normal impulse propagation. To explore the ionic mechanisms of block in Fhf2KO hearts, multicellular linear strand models incorporating FHF2-deficient Nav inactivation properties were constructed and faithfully recapitulated conduction abnormalities seen in mutant hearts. The mechanisms of conduction block in mutant strands with reduced gCaV or diminished Gj are very different. Enhanced Nav inactivation due to FHF2 deficiency shifts dependence onto calcium current (ICa) to sustain electrotonic driving force, axial current flow, and action potential (AP) generation from cell-to-cell. In the setting of diminished Gj, slower charging time from upstream cells conspires with accelerated Nav inactivation in mutant strands to prevent sufficient downstream cell charging for AP propagation.FHF2-dependent effects on Nav inactivation ensure adequate sodium current (INa) reserve to safeguard against numerous threats to reliable cardiac impulse propagation.
810MO Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial
Authors: B. Pothuri, S. Han, D. Chase, F. Heitz, R. Burger, L. Gaba, L. Van Le, E. Guerra, D. Bender, J. Korach, N.G. Cloven, P. Follana, J-F. Baurain, C. Pisano, U. Peen, J. Maenpaa, E. Bacqué, Y. Li, A. González Martín, B.J. Monk
Journal: Annals of Oncology (2020)
1335P Anti-tumour efficacy of cetuximab plus avelumab in NSCLC through induction of ADCC: Final data from CAVE-lung trial
Authors: M. Fasano, C.M. Della Corte, R. Di Liello, G. Barra, F. Cimmino, F. Sparano, G. Viscardi, M.L. Iacovino, F. Paragliola, V. Famiglietti, V. Ciaramella, V. Sforza, A. Morabito, E. Maiello, F. Ciardiello, F. Morgillo
Journal: Annals of Oncology (2020)